---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-285425"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2026-06-26T20:02:14+00:00"
generated_at: "2026-06-26T20:03:32.878019+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology enters $50M loan facility with HSBC; $10M drawn at close, refinances existing debt

## Summary
- Total facility up to $50M: $10M drawn at closing to refinance Oxford Finance/SVB loans; $20M available to June 30, 2028.
- Milestone-dependent $10M tranche tied to Phase 2 ASPEN-09 (Evorpacept) data and Phase 1 ALX2004 safety; $10M at lender discretion.
- Term loans mature June 1, 2030; interest at greater of Prime Rate or 6.0% per annum; monthly interest-only until July 2028 (or 2029 if milestone met).
- Secured by substantially all assets with negative pledge on IP; customary covenants and 2% prepayment fee in year one.

## SEC filing metadata
- accession: 0001193125-26-285425
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2026-06-26T20:02:14+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 1.02, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000119312526285425/0001193125-26-285425-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000119312526285425/alxo-20260625.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-285425
- JSON: https://secwatch.observer/filing/0001193125-26-285425.json
- Plain text: https://secwatch.observer/filing/0001193125-26-285425.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.